Adjuvant treatment

Phase 2Small molecule

GGERCOR - Multidisciplinary Oncology Cooperative Group

Adjuvant treatment is one of 44 small molecule programs targeting Neuroendocrine Carcinoma. It is currently in Phase 2.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

Neuroendocrine CarcinomaActive, not recruiting

Neuroendocrine CarcinomaPhase 2

Active, not recruiting

Competition

Competitive Landscape

96 competitors in Neuroendocrine Carcinoma

#DrugCompanyPhaseTrials

Tarlatamab-Dznl

Amgen

Phase 3

5 2

Tuoyi

CCoherus Oncology, Inc.

Phase 3

1 3

Inlyta

PPrism Pharmaceuticals

Phase 3

1 4

Xpovio

KKaryopharm Therapeutics Inc

Phase 3

—5

Wellcovorin

EEastern Cooperative Oncology Group

Sandostatin LAR

1 7

Keytruda

Merck & Co.

Phase 2

3 8

Tecentriq

Roche

Phase 2

2 9

Opdivo

Bristol-Myers Squibb

Phase 2

2 10

Imfinzi

AstraZeneca

Phase 2

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q1 2031

Phase 2Recruiting

Neuroendocrine Carcinoma

NCT04268121

Clinical

Trials by Indication[1]

Neuroendocrine Carcinoma1 trial

Efficacy of Neoadjuvant Chemotherapy in Terms of DFS in Patients With Localized Digestive Neuroendocrine Carcinomas

Recruiting·GGERCOR - Multidisciplinary Oncology Cooperative Group·Phase 2·NCT04268121·78 enrolled

Sources

References

[1]
ClinicalTrials.gov — 1 trial record for Adjuvant treatment. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — Adjuvant treatment compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for Adjuvant treatment. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — GERCOR - Multidisciplinary Oncology Cooperative Group company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Phase 2[1]
Company: GGERCOR - Multidisciplinary Oncology Cooperative Group

Adjuvant treatment

Status by Indication[3][1]

Competitive Landscape

Expected Milestones

Q1 2031

Trials by Indication[1]

Neuroendocrine Carcinoma1 trial

References

Drug Info

Quick Facts

Related News